Last reviewed · How we verify
Sufentanil II
Sufentanil is a potent synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation.
Sufentanil is a potent synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation. Used for Acute pain management, Perioperative analgesia and sedation.
At a glance
| Generic name | Sufentanil II |
|---|---|
| Also known as | Sufenta |
| Sponsor | Aarhus University Hospital |
| Drug class | Opioid agonist |
| Target | Mu-opioid receptor (OPRM1) |
| Modality | Small molecule |
| Therapeutic area | Pain management, Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Sufentanil acts as a selective agonist at mu-opioid receptors, which are distributed throughout the brain and spinal cord. By activating these receptors, it modulates pain perception and produces sedative effects. It is approximately 5-10 times more potent than fentanyl and is used for acute pain management and anesthesia support.
Approved indications
- Acute pain management
- Perioperative analgesia and sedation
Common side effects
- Respiratory depression
- Hypotension
- Bradycardia
- Nausea
- Dizziness
Key clinical trials
- Comparing the QoR of PECS Block and GA in Breast-conserving Surgery With Sentinel Lymph Node Biopsy (NA)
- Regional Anesthesia Techniques in Breast Surgery (NA)
- The Application of Pectoral Nerve II(PECS II)block in Breast Fibroadenoma Resection Surgery (NA)
- The Influence of Two Different CO2 Absorbers on Sevoflurane Consumption During Anaesthesia
- Stress, Anxiety and Type A Personality and Analgesics (PHASE4)
- Monitor-Guided Analgesia During General Anesthesia - Part II (NA)
- Large-scale Prospective Double-blind Randomized Controlled Trial of Pecs II Block for Breast Surgery (PHASE4)
- Labor Analgesia in the Latent Phrase (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sufentanil II CI brief — competitive landscape report
- Sufentanil II updates RSS · CI watch RSS
- Aarhus University Hospital portfolio CI